Use of Bevacizumab in recurrent glioblastoma: a scoping review and evidence map

Use of Bevacizumab in recurrent glioblastoma: a scoping review and evidence map

Abstract Background Glioblastoma (GBM) is the most malignant primary tumor in the brain, with poor prognosis and limited effective therapies. Although Bevacizumab (BEV) has shown promise in extending progression-free survival (PFS) treating GBM, there is no evidence for its ability to prolong overal...

Full description

Bibliographic Details
Main Authors: Minjie Fu, Zhirui Zhou, Xiao Huang, Zhenchao Chen, Licheng Zhang, Jinsen Zhang, Wei Hua, Ying Mao
Format: Article
Language:English
Published: BMC 2023-06-01
Series:BMC Cancer
Subjects:
Bevacizumab
Recurrent glioblastoma
Combined therapy
Quality of life
Online Access:https://doi.org/10.1186/s12885-023-11043-6

Internet

https://doi.org/10.1186/s12885-023-11043-6

Similar Items